The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1
A review of clinical trials to prevent mother-to-child HIV-1 transmission in Africa and inform rational intervention strategies
Lack of Epstein-Barr virus- and HIV-specific CD27− CD8+ T cells is associated with progression to viral disease in HIV-infection
TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy
Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans
Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy
Prevalence and clinical correlates of HIV viremia (`blips') in patients with previous suppression below the limits of quantification
Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases
Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection
Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay
Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996
Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya
Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia
Clinical use of lopinavir/ritonavir in a salvage therapy setting
Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients
HIV-1-specific CD8 T cell responses in a pediatric slow progressor infected as a premature neonate
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients
Risk factors for indinavir-related renal colic in HIV patients
The radiographic appearance of pneumococcal pneumonia in adults is unaltered by HIV-1-infection in hospitalized Kenyans
Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy
Reply to ‘Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy'
Rash-associated severe neutropenia as a side-effect of indinavir in HIV postexposure prophylaxis
Lack of ‘occult’ hepatitis B virus infection in HIV-infected patients
Population-level risk factors for HIV transmission and ‘the 4 Cities Study'
ERRATUM Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial) Hans-Jürgen Stellbrink, Jan van Lunzen, Michael Westby, Eithine O'Sullivan, Claus Schneider, Axel Adam, Lutwin Weitner, Birger Kuhlmann, Christian Hoffmann, Stefan Fenske, Philipp S. Aries, Olaf Degen, Christian Eggers, Heiko Petersen, Friedrich Haag, Heinz A. Horst, Klaus Dalhoff, Christiane Möcklinghoff, Nick Cammack, Klara Tenner-Racz and Paul Racz
ERRATUM Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants William E. Dowling, Bohye Kim, Carl J. Mason, K. Monique Wasunna, Uzma Alam, Lynne Elson, Deborah L. Birx, Merlin L. Robb, Francine E. McCutchan and Jean K. Carr